Experimental Spinocerebellar Ataxia Treatment Earns Orphan Drug Designation

According to a story from Bloomberg, the company Cadent Therapeutics recently announced that the company's experimental product candidate CAD-1883 has earned Orphan Drug Designation from the US Food and Drug…

Continue Reading Experimental Spinocerebellar Ataxia Treatment Earns Orphan Drug Designation

Phase 2 Clinical Trial for Microvillus Inclusion Disease Approved to Begin in Turkey

MVID Microvillus inclusion disease (MVID) is a rare, gastrointestinal disease which can cause impaired development in children. It is characterized by severe diarrhea which leads to dehydration and malnutrition. MVID…

Continue Reading Phase 2 Clinical Trial for Microvillus Inclusion Disease Approved to Begin in Turkey

Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment

According to a story from globenewswire.com, the genetic medicines company Homology Medicines, Inc. has recently announced that it has opened enrollment for its phase 1/2 clinical trial. This clinical trial…

Continue Reading Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment
ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
HeungSoon / Pixabay

ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial

According to a story from Ysios Capital, the biotechnology company Minoryx Therapeutics recently announced that the first patient has been dosed in the company's phase 2 clinical trial. This trial…

Continue Reading ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
Close Menu